The National Rare Disease Plan 2014 – 2018, published this month, outlines proposals for a new clinical care programme specifically for the treatment of rare diseases, which affect an estimated 6 to 8 per cent of people in their lifetime. Illnesses which affect fewer than five people in every 10,000 are considered “rare diseases”, with about 8,000 identified in Ireland.
Speaking at the launch Minister for Health James Reilly stated that a new plan for the treatment of rare disease in Ireland should lead to faster diagnoses, improved access to care and better support for patients and their families.
www.IPPOSI.ie
Some of the recommendations include the establishment of a dedicated national office for rare disease which would coordinate access to medical expertise and provide information to patients and medical practitioners about new treatments and clinical trials and for the development of a rare disease research network to enhance the quality of research in Ireland.
Alpha-1 antitrypsin is a vital protein produced by the liver to protect the lungs. It provides protection from the harmful effects of infections and inhaled irritants, particularly tobacco smoke. It can be easily measured by a simple blood test.
WhatisAlpha-1AntitrypsinDeficiency?
Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, after cystic fibrosis, is the commonest genetic disorder in Ireland. It severely affects more than 15,000 people, with another 250,000 carriers also at risk of lung and liver disease on the island of Ireland. It is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD).
HowDoIGetTested?
The Alpha-1 Foundation Ireland provides free testing for Alpha-1 as part of a national screening programme which is funded by the HSE. It is a simple blood test. For more details ring 01-8093871 or email alpha1@rcsi.ie
National Rare Disease Plan Launch
The National Rare Disease Plan 2014 – 2018, published this month, outlines proposals for a new clinical care programme specifically for the treatment of rare diseases, which affect an estimated 6 to 8 per cent of people in their lifetime. Illnesses which affect fewer than five people in every 10,000 are considered “rare diseases”, with about 8,000 identified in Ireland.
Speaking at the launch Minister for Health James Reilly stated that a new plan for the treatment of rare disease in Ireland should lead to faster diagnoses, improved access to care and better support for patients and their families.
www.IPPOSI.ie
Some of the recommendations include the establishment of a dedicated national office for rare disease which would coordinate access to medical expertise and provide information to patients and medical practitioners about new treatments and clinical trials and for the development of a rare disease research network to enhance the quality of research in Ireland.
Click here for some press coverage on the launch.
Info Centre
What is Alpha-1 Antitrypsin?
Alpha-1 antitrypsin is a vital protein produced by the liver to protect the lungs. It provides protection from the harmful effects of infections and inhaled irritants, particularly tobacco smoke. It can be easily measured by a simple blood test.
What is Alpha-1 Antitrypsin Deficiency?
Alpha-1 antitrypsin deficiency (Alpha-1) is a genetic condition which, after cystic fibrosis, is the commonest genetic disorder in Ireland. It severely affects more than 15,000 people, with another 250,000 carriers also at risk of lung and liver disease on the island of Ireland. It is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD).
How Do I Get Tested?
The Alpha-1 Foundation Ireland provides free testing for Alpha-1 as part of a national screening programme which is funded by the HSE. It is a simple blood test. For more details ring 01-8093871 or email alpha1@rcsi.ie